Janssen Romania head sees potential in risk-sharing agreements in local pharma sector

Ovidiu Posirca 10/11/2017 | 11:58

Christian Rodseth, managing director of Janssen Romania, says that risk-sharing agreements for innovative pharmaceuticals can work in Romania, citing the positive experience that the company has had in the British market.

“We need to invest more in radiotherapy equipment, we need a national cancer strategy,” said the executive during the launch event of White Book on the implementation of monitorization registries in the case of rare cancers.

Statistics show that each year there are 78,000 patients in Romania diagnosed with cancer, above the average in the European Union. The mortality rate stands at 48,000 per year.

The White Book, which is supported by the Italian Interuniversity Consortium (CINECA), the Collaborative Outcome Research Evaluation (CORE) body and communication consultancy Serban & Musneci Associates (SMA), outlines Italy’s experience in bringing more innovative drugs on the market. The study was supported by Janssen Romania.

Starting 2006, Italy implemented management entry agreements (MEA) which includes cost-volume/cost-volume-result agreements between drugs producers and healthcare insurance houses.

“To allow the successful implementation of these strategies, an important role is played by the informatization of the medical sector and the development of electronic registries for monitorization. This would permit the generation of complex analysis and reports – from demographics to specific clinical data, to financial data – ensuring the tracking and transparency of information in the medical sector,” say the authors of the study.

Roberto Musneci pointed that the electronic registries ensure the appropriateness of prescription, adding that Romania has initiated a cost-volume platform for new drugs which follows the success fee model. This means that the producer is paid by the state if patients are responsive to the innovative treatments.

A report by InoMed points out that only seven out of the 62 original cancer drugs approved in the 2008-2015 period are on the reimbursement list.

The authors of the study suggested that more drugs can be reimbursement list by closing more agreements on sharing costs.

Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue